Nephros Overview
Valuation check: NEPH's P/E ratio is 27.82, above the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow27.82
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Nephros (NEPH) currently reports a P/E ratio of 27.82. That is above the Healthcare sector average of 24.78. Use the charts on this page to explore Nephros's P/E ratio history and peer comparisons.
Nephros's P/E ratio of 27.82 is higher than the Healthcare sector average of 24.78. That is roughly 12.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Nephros's market price to a fundamental measure such as earnings, sales, or book value. At 27.82, NEPH can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 27.82, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Nephros, and consider following NEPH for alerts when major investors trade the stock.
Nephros is classified in the Healthcare sector. On P/E ratio, it currently shows 27.82 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NEPH with unrelated industries.
